Updated:
SYNthesis BioVentures
SYNthesis BioVentures is a private equity firm based in Parkville, Australia. It pursues a Venture Capital strategy, managing approximately $18.4 million in...
SYNthesis BioVentures
SYNthesis BioVentures is a private equity firm based in Parkville, Australia. It pursues a Venture Capital strategy, managing approximately $18.4 million in assets. The firm has $4.86 million in available capital and employs 3 staff.
General information
Firm type
Venture Capital
Year founded
2022
Location
Region
Oceania
Country
Australia
City
Parkville
Corporate office
Parkville, Victoria, Australia
Sector focus
Frequently asked questions
What stages does SYNthesis BioVentures target?
The firm publicly describes a stage-agnostic strategy covering early-stage venture, expansion and late-stage venture, general venture, and pre-IPO rounds. That breadth is atypical among Australian life sciences investors, who often specialize in either seed-stage academic spinouts or public-company crossover rounds rather than both.
Is SYNthesis BioVentures connected to the Parkville biomedical precinct?
Yes. The firm is headquartered in Parkville, Victoria, which is home to the Melbourne Biomedical Precinct — one of Australia's largest concentrations of medical research institutes, including the Walter and Eliza Hall Institute, the Peter Doherty Institute, and the corporate headquarters of CSL Limited. Geographic proximity to translational research assets is a key sourcing characteristic for firms based in this location.
Does SYNthesis BioVentures invest outside Australia?
The firm's public profile is Australia-focused, consistent with its Parkville headquarters. However, life sciences investors in the Melbourne precinct commonly evaluate opportunities in New Zealand and broader Asia-Pacific markets given the regional flow of IP and talent. No specific international investments have been confirmed by the firm.
What therapeutic areas does SYNthesis BioVentures focus on?
Specific therapeutic area exclusions or mandates have not been publicly disclosed. Given the firm's generalist life-sciences stage coverage and the composition of the Parkville research ecosystem, typical exposure would span therapeutics, medical devices, diagnostics, and digital health — though no portfolio-level data is available to confirm active weighting across these sub-sectors.
Has SYNthesis BioVentures disclosed its assets under management?
No. The firm does not publish an AUM figure, and no regulatory filing or media report has attributed a specific number to its current or historical funds. The firm's public financial disclosures are limited.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: